Homer Joshua A, Johnson Robert M, Koelln Rebecca A, Moorhouse Adam D, Moses John E
Cancer Center, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA.
Nat Rev Bioeng. 2025 Mar;3(3):213-229. doi: 10.1038/s44222-024-00250-w. Epub 2024 Oct 15.
Multidrug-resistant bacteria, especially those that defy even last-resort antibiotics, are causing a global health crisis fueled by antibiotic overuse and misuse as well as the lack of new antibiotic development. Multidrug-resistant bacteria compromise our ability to effectively treat infections, impacting medical procedures like surgeries and cancer treatments while increasing illness duration, mortality rates and healthcare costs. In this Review, we discuss reengineering approaches for existing antibiotics to address multidrug-resistant bacterial infections. We outline how antibiotic activity against drug-resistant bacteria can be increased through structural modifications and by engineering polyvalent drugs and combination therapies, designed to overcome drug resistance mechanisms. Finally, we examine regulatory and translational challenges for antibiotic reengineering, highlighting the need for antibiotic stewardship and global guidelines.
多重耐药菌,尤其是那些对甚至最后手段的抗生素都产生耐药的细菌,正引发一场全球健康危机,这场危机是由抗生素的过度使用和滥用以及新抗生素研发的缺乏所推动的。多重耐药菌损害了我们有效治疗感染的能力,影响了诸如手术和癌症治疗等医疗程序,同时增加了疾病持续时间、死亡率和医疗成本。在本综述中,我们讨论了对现有抗生素进行重新设计以应对多重耐药菌感染的方法。我们概述了如何通过结构修饰以及设计用于克服耐药机制的多价药物和联合疗法来提高抗生素对耐药菌的活性。最后,我们审视了抗生素重新设计在监管和转化方面的挑战,强调了抗生素管理和全球指南的必要性。
Nat Rev Bioeng. 2025-3
Cochrane Database Syst Rev. 2017-2-9
Cochrane Database Syst Rev. 2013-4-30
Cochrane Database Syst Rev. 2016-10-20
Cochrane Database Syst Rev. 2022-5-10
Cochrane Database Syst Rev. 2022-4-26
NPJ Antimicrob Resist. 2025-5-30
Ann Clin Microbiol Antimicrob. 2023-7-5
Front Pharmacol. 2023-6-12
J Antibiot (Tokyo). 2023-8
Nat Rev Microbiol. 2023-8
Antimicrob Resist Infect Control. 2023-4-19
Proc Natl Acad Sci U S A. 2023-4-11